Protocol to Profit: COVID-19 Treatment and Remdesivir
A 2019 study of antiviral medications in the Democratic Republic of Congo, funded by the National Institute of Allergy and Infectious Diseases (NIAID), showed Gilead Sciences’ antiviral medication Remdesivir to have a 53% mortality rate. The study recommended against any further use of Remdesivir in any patients. Barely a year later, in April 2020, NIAID…
